421 related articles for article (PubMed ID: 18339187)
1. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
3. [The neurological manifestations of Fabry disease. A review].
Firsov KV; Kotov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
5. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
6. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
7. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease in children and the effects of enzyme replacement treatment.
Pintos-Morell G; Beck M
Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
[TBL] [Abstract][Full Text] [Related]
9. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
13. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
14. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
15. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
Ramaswami U
Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
[TBL] [Abstract][Full Text] [Related]
18. Natural history of Fabry disease in females in the Fabry Outcome Survey.
Deegan PB; Baehner AF; Barba Romero MA; Hughes DA; Kampmann C; Beck M;
J Med Genet; 2006 Apr; 43(4):347-52. PubMed ID: 16227523
[TBL] [Abstract][Full Text] [Related]
19. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
Demontis R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]